Literature DB >> 18155021

T cells for suicide gene therapy: activation, functionality and clinical relevance.

Gabriele Hollatz1, M Grez, S Mastaglio, R Quaritsch, S Huenecke, F Ciceri, C Bonini, R Esser, T Klingebiel, J Kreuter, U Koehl.   

Abstract

In order to control graft-versus-host disease after donor lymphocyte infusion, T cells can be retrovirally transduced with a suicide gene. However, the immune competence of activated T cells appears compromised, responsible for reduced alloreactivity. The present study compared different activation protocols using soluble or bead-coupled antibodies regarding T-cell subtype expansion capacity and functionality. T cells were purified on a laboratory and clinical scale using both CD3 and CD4/CD8 antibodies for selection, leading to a mean purity of 96%. Transductions were performed with a GMP-grade CD34/HSV-TK vector. Activation with soluble CD3/CD28-antibodies +1000 U/ml IL-2 induced a 50-fold expansion of T cells over 14 days, whereas T cells activated with bead-coupled antibodies only expanded 2-4-fold restricted to the first week. Apart from using soluble antibodies, proliferation was highly IL-2 dependent. Expansion of CMV-specific T cells coincided with the expansion of whole CD3(+) cells. Soluble antibodies and higher IL-2 concentrations preferentially stimulated CD8(+) T cells, while bead-coupled antibodies +20 U/ml IL-2 preserved the CD4/CD8 ratio. Irrespective of the activation protocol, there was a shift from a naive to memory phenotype. When activated with soluble antibodies, mainly CD8(+) T cells were transduced. Furthermore, Th1/Th2 cytokine secretion was reduced. In contrast, CD4(+)/CD8(+) T cells activated with bead-coupled antibodies were rather homogenously transduced and cytokine secretion did not appear to be affected.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155021     DOI: 10.1016/j.jim.2007.11.007

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

Review 1.  Use of tumour-responsive T cells as cancer treatment.

Authors:  Mary L Disis; Helga Bernhard; Elizabeth M Jaffee
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

2.  Identification of radiation-induced expression changes in nonimmortalized human T cells.

Authors:  Era L Pogosova-Agadjanyan; Wenhong Fan; George E Georges; Jeffrey L Schwartz; Crystal M Kepler; Hana Lee; Amanda L Suchanek; Michelle R Cronk; Ariel Brumbaugh; Julia H Engel; Michi Yukawa; Lue P Zhao; Shelly Heimfeld; Derek L Stirewalt
Journal:  Radiat Res       Date:  2010-11-17       Impact factor: 2.841

3.  The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.

Authors:  Paul C Tumeh; Richard C Koya; Thinle Chodon; Nicholas A Graham; Thomas G Graeber; Begoña Comin-Anduix; Antoni Ribas
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

4.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

5.  Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products.

Authors:  Christoph Priesner; Krasimira Aleksandrova; Ruth Esser; Nadine Mockel-Tenbrinck; Jana Leise; Katharina Drechsel; Michael Marburger; Andrea Quaiser; Lilia Goudeva; Lubomir Arseniev; Andrew D Kaiser; Wolfgang Glienke; Ulrike Koehl
Journal:  Hum Gene Ther       Date:  2016-10       Impact factor: 5.695

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.